Literature DB >> 24216129

Value of anatomic site, histology and clinicopathological parameters for prediction of lymph node metastasis and overall survival in head and neck melanomas.

Tobias Ettl1, Serkan Irga2, Steffen Müller2, Christian Rohrmeier3, Torsten E Reichert2, Stephan Schreml4, Martin Gosau2.   

Abstract

INTRODUCTION: Head and neck melanoma compromises a group of aggressive tumours with varying clinical courses. This analysis was performed to find anatomic and clinicopathological parameters predictive for lymph node metastasis and overall survival.
MATERIAL AND METHODS: Data and outcome of 246 patients with a malignant melanoma in the head and neck region were retrospectively analyzed for predictive parameters.
RESULTS: Lentigo maligna melanoma (n = 115) was the most frequent histology, followed by superficial spreading (n = 63) and nodular melanoma (n = 52). More than half of the melanomas (n = 138) were in the face. Tumours of the face and anterior scalp metastasized to lymph nodes of the neck and parotid gland, whereas tumours of the posterior scalp and neck also metastasized to the nuchal region. Advanced Clark level, presence of tumour ulceration and younger age were the strongest predictors of lymph node metastasis in multivariate regression analysis (p < 0.05), but anatomic site, histological subtype and tumour thickness were also associated with lymph node metastasis. Lymph node metastases, distant metastases, ulceration, nodular subtype and non-facial site of origin were the strongest negative prognostic parameters for disease-specific overall survival (p < 0.05). In contrast, the width of resection margin (<1 cm vs. 1-2 cm vs. >2 cm) did not correlate with tumour recurrence and overall survival (p > 0.05).
CONCLUSION: Histological subtype diagnosis, anatomic site of origin as well as the established factors tumour thickness, ulceration and depth of invasion are prognostic indicators of cervical lymph node metastasis and overall survival. A resection margin of at least 1 cm seems sufficient in head and neck melanoma. The status of sentinel lymph node biopsy and neck dissection has to be proven within the next years.
Copyright © 2013 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Head and neck; Melanoma; Neck dissection; Prognosis; Resection margin

Mesh:

Year:  2013        PMID: 24216129     DOI: 10.1016/j.jcms.2013.09.007

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  6 in total

1.  Parotid melanoma of unknown primary.

Authors:  Jeffrey F Scott; Cheryl L Thompson; Ritva Vyas; Kord Honda; Chad Zender; Rod Rezaee; Pierre Lavertu; Henry Koon; Kevin D Cooper; Meg R Gerstenblith
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-13       Impact factor: 4.553

2.  Dermoscopic and clinical features of head and neck melanoma.

Authors:  Fatma Pelin Cengiz; Abdurrahman Bugra Cengiz; Nazan Emiroglu; Ela Comert; Rainer Hofmann Wellenhof
Journal:  An Bras Dermatol       Date:  2015 Jul-Aug       Impact factor: 1.896

3.  Metastatic Malignant Melanoma of Parotid Gland with a Regressed Primary Tumor.

Authors:  M Mustafa Kılıçkaya; Giray Aynali; Ali Murat Ceyhan; Metin Çiriş
Journal:  Case Rep Otolaryngol       Date:  2016-07-05

4.  Head and neck melanoma: outcome and predictors in a population-based cohort study.

Authors:  Steffen Spoerl; Gerrit Spanier; Elena Reiter; Michael Gerken; Sebastian Haferkamp; Jirka Grosse; Konstantin Drexler; Tobias Ettl; Monika Klinkhammer-Schalke; René Fischer; Silvia Spoerl; Torsten E Reichert; Christoph Klingelhöffer
Journal:  Head Face Med       Date:  2021-10-22       Impact factor: 2.246

Review 5.  Predictors of Nodal Metastasis in Cutaneous Head and Neck Cancers.

Authors:  Albert Y Han; Maie A St John
Journal:  Curr Oncol Rep       Date:  2022-04-08       Impact factor: 5.945

6.  Distribution of skin cancers of the head and neck according to anatomical subunit.

Authors:  Handan Derebaşınlıoğlu
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-05-28       Impact factor: 2.503

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.